Targeted degradation of activating estrogen receptor α ligand-binding domain mutations in human breast cancer
ConclusionERD-148 inhibits the growth of ER-positive breast cancer cells via downregulating ER α with comparable potency to Fulvestrant with marginal non-specific toxicity. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - February 17, 2020 Category: Cancer & Oncology Source Type: research

The association of delay in curative intent treatment with survival among breast cancer patients: findings from the Women ’s Health Initiative
ConclusionsA delay to a single treatment modality and delay to a greater extent an accumulation of delays were associated with higher BCSM and ACM after BC. Timely care throughout the continuum of breast cancer treatment is important for optimal outcomes. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - February 15, 2020 Category: Cancer & Oncology Source Type: research

Trend and survival benefit of Oncotype DX use among female hormone receptor-positive breast cancer patients in 17 SEER registries, 2004 –2015
AbstractPurposeTo examine (1) the trend and associated factors of Oncotype DX (ODX) use among hormone receptor-positive (HR+) breast cancer (BC) patients in 2004 –2015; (2) the trend of reported chemotherapy by Recurrence Score (RS); and (3) the survival differences associated with ODX use.MethodsODX data from Genomic Health Inc. were linked with 17 SEER registries data. HR  + BC cases with lymph node negative (N0) or 1–3 positive LNs (N1) from 2004–2015 were analyzed. The Cochrane-Armitage trend test, logistic regression, Kaplan–Meier survival curve, and stratified Cox model were perf...
Source: Breast Cancer Research and Treatment - February 14, 2020 Category: Cancer & Oncology Source Type: research

Phase II trial of eribulin in patients who do not achieve pathologic complete response (pCR) following neoadjuvant chemotherapy
ConclusionAdministration of adjuvant eribulin after neoadjuvant chemotherapy was feasible and well tolerated. The 24-month DFS rate did not reach the study target levels in any of the cohorts and was similar to DFS previously described in these cohorts following neoadjuvant chemotherapy alone. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - February 14, 2020 Category: Cancer & Oncology Source Type: research

Management of the axilla in breast cancer:  outcome analysis in a series of ductal versus lobular invasive cancers
ConclusionsILC histology is not associated with higher risk of further metastasis at ALND in our analysis. However, surgical management decisions should be taken considering tumor histotype, biology and expected sensitivity to adjuvant therapies. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - February 14, 2020 Category: Cancer & Oncology Source Type: research

Trends of female and male breast cancer incidence at the global, regional, and national levels, 1990 –2017
ConclusionsBreast cancer incidence rates are increasing in most countries in both sexes, although the epidemiological features were not completely shared between FBC and MBC. More emphases should be placed on breast cancer primary prevention and the prevention strategies might need to be tailored for both FBC and MBC. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - February 13, 2020 Category: Cancer & Oncology Source Type: research

Three-dimensional microanatomy of human nipple visualized by X-ray dark-field computed tomography
ConclusionsXDFI-CT is useful for exploring the microanatomy of the human nipple and might be used for non-invasive nipple diagnosis in the future. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - February 13, 2020 Category: Cancer & Oncology Source Type: research

Inflammatory breast cancer cells are characterized by abrogated TGF β1-dependent cell motility and SMAD3 activity
This study has investigated the hypothesis that TGF β signaling is implicated in the molecular biology of IBC.MethodsTGF β1-induced cell motility and gene expression patterns were investigated in three IBC and three non-IBC (nIBC) cell lines. Tissue samples from IBC and nIBC patients were investigated for the expression of nuclear SMAD2, SMAD3, and SMAD4. SMAD protein levels were related to gene expression data.ResultsTGF β1-induced cell motility was strongly abrogated in IBC cells (P = 0.003). Genes differentially expressed between IBC and nIBC cells post TGFβ1 exposure revealed atte...
Source: Breast Cancer Research and Treatment - February 10, 2020 Category: Cancer & Oncology Source Type: research

Male breast cancer: a closer look at patient and tumor characteristics and factors that affect survival using the National Cancer Database
AbstractObjectiveTo comprehensively describe the tumor and clinical characteristics of breast cancer in a cohort of male patients and to assess the factors that affect survival.BackgroundMuch of the standard care of male breast cancer is based on the diagnosis and treatment strategies of female breast cancer. However, important clinical differences between the two have been elucidated, which suggests the need for unique attention to male breast cancer.MethodsWe evaluated the records of male patients who were diagnosed with breast cancer between 2004 and 2015 using the National Cancer Database (NCDB). Data obtained were dem...
Source: Breast Cancer Research and Treatment - February 10, 2020 Category: Cancer & Oncology Source Type: research

High serum levels of periostin are associated with a poor survival in breast cancer
In this study, we analyzed serum levels of periostin in a cohort of 509 primary, non-metastatic breast cancer patients. Disseminated tumor cell (DTC) status was determined using bone marrow aspirates obtained from the anterior iliac crests. Periostin levels were stratified according to several clinical parameters and Pearson correlation analyses were performed. Kaplan –Meier survival curves were assessed by using the log-rank (Mantel–Cox) test. To identify prognostic factors, multivariate Cox regression analyses were used.ResultsMean serum levels of periostin were 505  ± 179 pmol/l. In...
Source: Breast Cancer Research and Treatment - February 10, 2020 Category: Cancer & Oncology Source Type: research

Nomogram-based estimate of axillary nodal involvement in ACOSOG Z0011 (Alliance): validation and association with radiation protocol variations
AbstractPurposeA substantial proportion of patients enrolled on ACOSOG Z0011 received protocol-deviant radiation treatment. It is currently unknown whether these deviations involved the use of more extensive fields in patients at higher nomogram-predicted risk.MethodsWe used the M.D. Anderson (MDA) and Memorial Sloan-Kettering (MSK) nomograms to estimate risk of additional positive axillary nodes using surgical pathology information. In the control arm, we compared axillary dissection (AD) findings to nomogram-predicted estimates for validation. We used logistic regression to evaluate whether nomogram-estimated higher risk...
Source: Breast Cancer Research and Treatment - February 10, 2020 Category: Cancer & Oncology Source Type: research

The implications of BRCA loss of heterozygosity (LOH) and deficient mismatch repair gene (dMMR) expression in the breast cancer of a patient with both inherited breast and ovarian cancer syndrome (BRCA2) and Lynch syndrome (MLH1)
ConclusionThe patient presented represents the first reported case where both next generation sequencing (NGS) forBRCA LOH and MMR IHC testing of her breast cancer were performed and underscores the importance of using NGS including the reported mutational allelic frequency (MAF) and IHC use to predict the likely responsiveness to the recently approved PARP inhibitors and checkpoint inhibitor therapies (Robson et al in N Engl J Med 377:523 –533, 2017, Lemery et al in 377(15):1409–1412,https://doi.org/10.1056/NEJMp1709968, 2017), key because the gatekeeper transforming event for tumors related to inherited cance...
Source: Breast Cancer Research and Treatment - February 10, 2020 Category: Cancer & Oncology Source Type: research

Neoadjuvant therapy and sentinel lymph node biopsy in HER2-positive breast cancer patients: results from the PEONY trial
ConclusionsFor clinical ALN negative patients, HER2-positive subtype is found to have high node negative rate by pathology and it is recommended to undergo SLNB after NAT. For patients with positive ALNs who convert to negative, the false-negative rate is high. Dual tracer mapping, more than 2 SLNs detected, more than 1 SLN identified plus the clips placed are the guarantees for lower false-negative rate. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - February 7, 2020 Category: Cancer & Oncology Source Type: research

pHLIP(Var7)-P1AP suppresses tumor cell proliferation in MDA-MB-231 triple-negative breast cancer by targeting protease activated receptor 1
ConclusionPAR1 was highly expressed on the surface of MDA-MB-231 cells. pHLIP(Var7)-P1AP can effectively target MDA-MB-231 cells in an acidic environment and inhibit the growth of MDA-MB-231 cells by inhibiting the signal transduction of PAR1/G protein. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - February 7, 2020 Category: Cancer & Oncology Source Type: research

Tertiary lymphoid structures and associated plasma cells play an important role in the biology of triple-negative breast cancers
AbstractPurposeTriple-negative breast cancers (TNBC) are aggressive tumours that exhibit abundant lymphoid infiltrates which modulate tumour behaviour. Recent findings suggest that TNBC with higher densities of plasma cells are associated with a favourable prognosis, and tertiary lymphoid structures (TLS) have prognostic significance. Here, we studied the phenotype and function of plasma cells in TNBCs by assessing their association with IgG Kappa light chain expression, B cells, and TLS.MethodsA retrospective analysis of 269 TNBC cases was performed. Tumour-infiltrating CD38+  plasma cells, CD20+ B cells, an...
Source: Breast Cancer Research and Treatment - February 7, 2020 Category: Cancer & Oncology Source Type: research

Management of brain metastases in breast cancer: a review of current practices and emerging treatments
ConclusionsBCBM management is an increasing clinical concern. Multidisciplinary management combining the strengths of surgical, systemic, and radiation treatment modalities with prospective trials incorporating knowledge from the basic and translational sciences will ultimately lead to improved clinical outcomes for BCBM patients. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - February 6, 2020 Category: Cancer & Oncology Source Type: research

GLL398, an oral selective estrogen receptor degrader (SERD), blocks tumor growth in xenograft breast cancer models
ConclusionsThis study demonstrates GLL398 is an oral SERD that has therapeutic efficacy in clinically relevant breast tumor models. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - February 6, 2020 Category: Cancer & Oncology Source Type: research

UK Interdisciplinary Breast Cancer Symposium 2020
(Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - February 6, 2020 Category: Cancer & Oncology Source Type: research

Oncologic safety of immediate autologous fat grafting for reconstruction in breast-conserving surgery
Conclusions and relevanceAt a mean follow-up of 5  years, no significant differences in locoregional recurrence rates were found between patients who received immediate AFG and those who underwent breast-conserving surgery alone. These findings corroborate previous research demonstrating the oncological safety of immediate AFG reconstruction, furt her suggesting that this technique as a safe, effective way to achieve optimal cosmetic outcomes in primary breast cancer surgery without jeopardizing oncologic outcomes. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - February 6, 2020 Category: Cancer & Oncology Source Type: research

CYP24A1 polymorphisms and breast cancer risk
(Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - February 6, 2020 Category: Cancer & Oncology Source Type: research

Multiparametric radiomics methods for breast cancer tissue characterization using radiological imaging
AbstractBackground and purposeMultiparametric radiological imaging is vital for detection, characterization, and diagnosis of many different diseases. Radiomics provide quantitative metrics from radiological imaging that may infer potential biological meaning of the underlying tissue. However, current methods are limited to regions of interest extracted from a single imaging parameter or modality, which limits the amount of information available within the data. This limitation can directly affect the integration and applicable scope of radiomics into different clinical settings, since single image radiomics are not capabl...
Source: Breast Cancer Research and Treatment - February 4, 2020 Category: Cancer & Oncology Source Type: research

Accelerated aging in breast cancer survivors and its association with mortality and cancer recurrence
ConclusionAging-related physical changes/symptoms are commonly presented at 18 months after breast cancer diagnosis and are associated with worse prognosis.ImpactOur findings highlight the concern of accelerated aging among breast cancer survivors. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - February 4, 2020 Category: Cancer & Oncology Source Type: research

The prognostic value of HER2 status and efficacy of anti-HER2 therapy in patients with HR-positive mucinous breast cancer: a nationwide study from the Korean Breast Cancer Society
AbstractPurposeThe effect of human epidermal growth factor receptor 2 (HER2) status on mucinous carcinoma (MC) of the breast is unknown due to the rarity of HER2-positive cases. We evaluated the prognostic value of HER2 status and the efficacy of anti-HER2 therapy in patients with hormone receptor (HR)-positive MC.MethodsFrom the data of 154,661 patients recorded in the Korean Breast Cancer Registry between January 1990 and August 2016, 3076 (2.0%) were diagnosed with MC. Overall survival (OS) according to HER2 status and anti-HER2 therapy was analyzed using Kaplan –Meier estimates. Multivariate analysis was performe...
Source: Breast Cancer Research and Treatment - February 4, 2020 Category: Cancer & Oncology Source Type: research

The role of Micro-CT in imaging breast cancer specimens
ConclusionsMicro-CT provides full 3D images of breast cancer specimens, allowing one to identify, in minutes rather than hours, while the patient is in OR, margin-positive cancers together with information on where the cancer touches the edge, in a fashion more accurate than possible from the histology slides alone. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - February 4, 2020 Category: Cancer & Oncology Source Type: research

Clinical significance of gene mutation in ctDNA analysis for hormone receptor-positive metastatic breast cancer
In conclusion, assessment ofESR1 mutation and cfDNA concentration could be useful in predicting prognosis for HR-MBCs. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - February 4, 2020 Category: Cancer & Oncology Source Type: research

The influence on quality of life of intermittent scheduling in first- and second-line chemotherapy of patients with HER2-negative advanced breast cancer
AbstractBackgroundThe Stop&Go study randomized patients with advanced breast cancer to intermittent (two times four) or continuous (eight subsequent cycles) first- and second-line chemotherapy.MethodsQoL was measured with RAND-36 questionnaires every 12  weeks. The primary objective was to estimate differences in changes from baseline between intermittent and continuous treatment. An effect size of 0.5 SD (5 points) was considered clinically meaningful.ResultsA total of 398 patients were included with a median follow-up of 11.4  months (IQR 5.6–22.2). Mean physical QoL baseline scores were 38.0 resp. 38...
Source: Breast Cancer Research and Treatment - February 1, 2020 Category: Cancer & Oncology Source Type: research

Clinicopathological significance of lipocalin 2 nuclear expression in invasive breast cancer
ConclusionsTumour cell expression of LCN2 plays a role in breast cancer progression with loss of its nuclear expression which is associated with aggressive features and poor outcome. Further functional analysis is warranted to confirm the relationship between the subcellular localisation LCN2 and behaviour of breast cancer. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - February 1, 2020 Category: Cancer & Oncology Source Type: research

Histone deacetylase (HDAC) inhibitors and doxorubicin combinations target both breast cancer stem cells and non-stem breast cancer cells simultaneously
ConclusionIn conclusion, this study demonstrates the potential of HDACi as therapeutic options, either as monotherapy or in combination with chemotherapeutics against refractory breast cancer. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - February 1, 2020 Category: Cancer & Oncology Source Type: research

Exome sequencing study of Russian breast cancer patients suggests a predisposing role for USP39
ConclusionsThis study suggests the role of a rare splicing variant inBC susceptibility.USP39 encodes an ubiquitin-specific peptidase that regulates cancer-relevant tumor suppressors including CHEK2. Further epidemiological and functional studies involving these gene variants are warranted. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - February 1, 2020 Category: Cancer & Oncology Source Type: research

The orphan nuclear receptor estrogen-related receptor beta (ERR β) in triple-negative breast cancer
ConclusionsDecreasedESRRB mRNA expression and distinct patterns of ERR β isoform subcellular localization and transcription factor activity are key features in TNBC/BLBC. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - February 1, 2020 Category: Cancer & Oncology Source Type: research

Weight trajectories in women receiving systemic adjuvant therapy for breast cancer
This study investigates weight trajectories in early BC patients at 2  years post-primary treatment, examining potential contributing factors such as age, race, and receipt of chemotherapy, anti-HER-2 therapy, and endocrine treatment (ET).MethodsA single institution cohort of newly diagnosed women age 21 and older with early breast cancer patients (Stage 0 –3) were identified by retrospective chart review (diagnosis year 1995 to 2016). Log-binomial regression models for net weight changes at 2 years post-primary treatment including patient demographic, clinical, and treatment characteristics.ResultsThe fina...
Source: Breast Cancer Research and Treatment - February 1, 2020 Category: Cancer & Oncology Source Type: research

Pre- and post-diagnostic intake of whole grain and dairy products and breast cancer prognosis: the Danish Diet, Cancer and Health cohort
ConclusionPre-diagnostic intake of oatmeal/muesli was associated with lower all-cause mortality,  and post-diagnostic intake of rye bread was associated with higher breast cancer specific mortality. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - February 1, 2020 Category: Cancer & Oncology Source Type: research

Results of a phase I, non-randomized study evaluating a Magnetic Occult Lesion Localization Instrument (MOLLI) for excision of non-palpable breast lesions
ConclusionsThe MOLLI guidance system is a reliable and accurate method for intraoperative localization of non-palpable breast lesions. Further evaluation of the MOLLI system in studies against current standards of care is required to demonstrate system cost-effectiveness and improved patient-reported outcomes. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - February 1, 2020 Category: Cancer & Oncology Source Type: research

The prognostic value of NRF2 in breast cancer patients: a systematic review with meta-analysis
AbstractPurposeNuclear factor E2-related factor 2 (NRF2) is a transcription factor that plays a major role in the regulation of intracellular antioxidant response. The effect of NRF2 overexpression in many malignancies is still unclear and recent meta-analysis correlated NRF2 overexpression with poor prognosis in a variety of human cancers. However, the effect of NRF2 overexpression in breast cancer is still unclear. Thus, the main goal of this work was to clarify the role of NRF2 expression in survival and relapse of breast cancer patients by performing a systematic review according to PRISMA (Preferred Reporting Items fo...
Source: Breast Cancer Research and Treatment - February 1, 2020 Category: Cancer & Oncology Source Type: research

Tumor microenvironment and breast cancer survival: combined effects of breast fat, M2 macrophages and hyaluronan create a dismal prognosis
AbstractPurposeTumor microenvironment, including inflammatory cells, adipocytes and extracellular matrix constituents such as hyaluronan (HA), impacts on cancer progression. Systemic metabolism also influences tumor growth e.g. obesity and type 2 diabetes (T2D) are risk factors for breast cancer. Here, in 262 breast cancer cases, we explored the combined impacts on survival of M2-like tumor associated macrophages (TAMs), the abundance of breast fat visualized as low density in mammograms, and tumor HA, and their associations with T2D.MethodsMammographic densities were assessed visually from the diagnostic images and dichot...
Source: Breast Cancer Research and Treatment - February 1, 2020 Category: Cancer & Oncology Source Type: research

Axillary lymph node dissection in node-positive breast cancer: are ten nodes adequate and when is enough, enough?
AbstractPurposeNational guidelines define adequate axillary lymph node dissections as those yielding  ≥ 10 lymph nodes (LNs). We aimed to identify the optimal LN yield among node-positive patients.MethodsUsing the National Cancer Data Base (2010 –2015), we categorized node-positive patients as follows: (1) neoadjuvant chemotherapy (NAC, cN1–3 or ypN1mi-3) or (2) upfront surgery (pN1–3). A restricted cubic splines model was used to estimate LN retrieval thresholds associated with change in overall survival (OS).Results129,685 patients were identified: 21.2% NAC, 78.8% upfront surgery. Low,...
Source: Breast Cancer Research and Treatment - February 1, 2020 Category: Cancer & Oncology Source Type: research

Socioeconomic status differs between breast cancer patients treated with mastectomy and breast conservation, and affects patient-reported preoperative information
AbstractPurposeBreast cancer treatment is reported to be influenced by socioeconomic status (SES). Few reports, however, stem from national, equality-based health care systems. The aim of this study was to analyse associations between SES, rates of breast-conserving surgery (BCS), patient-reported preoperative information and perceived involvement in Sweden.MethodsAll women operated for primary breast cancer in Sweden in 2013 were included. Tumour and treatment data as well as socioeconomic data were retrieved from national registers. Postal questionnaires regarding preoperative information about breast-conserving options ...
Source: Breast Cancer Research and Treatment - February 1, 2020 Category: Cancer & Oncology Source Type: research

Correction to: Pharmacokinetic and pharmacodynamic analysis of fulvestrant in preclinical models of breast cancer to assess the importance of its estrogen receptor- α degrader activity in antitumor efficacy
The article Pharmacokinetic and pharmacodynamic analysis of fulvestrant in preclinical models of breast cancer to assess the importance of its estrogen receptor- α degrader activity in antitumor efficacy, written by Suzanne E. Wardell, Alexander P. Yllanes, Christina A. Chao, Yeeun Bae, Kaitlyn J. Andreano, Taylor K. Desautels, Kendall A. Heetderks, Jeremy T. Blitzer, John D. Norris, Donald P. McDonnell, was originally published electronically on the publis her’s internet portal on September 27, 2019 without open access. With the author(s)’ decision to opt for Open Choice the copyright of the article chan...
Source: Breast Cancer Research and Treatment - February 1, 2020 Category: Cancer & Oncology Source Type: research

Anastrozole plus fulvestrant vs. anastrozole alone for hormone receptor-positive advanced breast cancer: a meta-analysis of randomized controlled trials
ConclusionsFor HR-positive advanced breast cancer patients, the combination of anastrozole and fulvestrant appears to be superior to anastrozole alone in extending PFS and OS, despite relatively serious AEs. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - February 1, 2020 Category: Cancer & Oncology Source Type: research

Associations between breast cancer subtype and neighborhood socioeconomic and racial composition among Black and White women
ConclusionThe relationships between neighborhood composition, neighborhood socioeconomic status, and odds of TNBC differ by race and age. Racially patterned social factors warrant further exploration in breast cancer subtype disparities research. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - January 30, 2020 Category: Cancer & Oncology Source Type: research

Quantitative digital imaging analysis of HER2 immunohistochemistry predicts the response to anti-HER2 neoadjuvant chemotherapy in HER2-positive breast carcinoma
ConclusionsHER2 IHC DIA connectivity is the most important factor predicting pCR to anti-HER2 neoadjuvant chemotherapy in patients with HER2-positive breast cancer. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - January 30, 2020 Category: Cancer & Oncology Source Type: research

Increased number of intratumoral IL-17+ cells, a harbinger of the adverse prognosis of triple-negative breast cancer
ConclusionThe study indicates that IL-17 is overexpressed in intratumoral stromal cells of TNBC-NST. The overexpression of IL-17 might engage in active tumor microangiogenesis through its signal transduction pathways resulting in increased tumor secretion of VEGFA, and then promote tumor progression. IL-17 might serve as a potential new target for individualized therapy to TNBC-NST patients by development of specific antibodies. Additional study is deemed to further explore the role of IL-17+ stromal cells in breast cancer. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - January 29, 2020 Category: Cancer & Oncology Source Type: research

High risk of breast cancer in women with biallelic pathogenic variants in CHEK2
This study compared the prevalence of breast and other cancers in women with monoallelic and biallelicCHEK2 PVs.MethodsCHEK2 PV carriers were identified through commercial hereditary cancer panel testing (09/2013 –07/2019). We compared cancer histories of 6473 monoallelic carriers to 31 biallelic carriers. Breast cancer risks were estimated using multivariate logistic regression and are reported as odds ratios (OR) with 95% confidence intervals (CI).ResultsBreast cancer frequency was higher among biallelicCHEK2 PV carriers (80.6%, 25/31) than monoallelic carriers (41.2%, 2668/6473;p 
Source: Breast Cancer Research and Treatment - January 28, 2020 Category: Cancer & Oncology Source Type: research

Patient-reported outcome after oncoplastic breast surgery compared with conventional breast-conserving surgery in breast cancer
ConclusionThe present study indicates better outcomes of HRQoL for breast cancer patients treated with OBS as compared to patients treated with BCS. There was no increase in physical discomfort among OBS patients despite more extensive surgery. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - January 27, 2020 Category: Cancer & Oncology Source Type: research

The generalisability of randomised clinical trials: an interim external validity analysis of the ongoing SENOMAC trial in sentinel lymph node-positive breast cancer
AbstractPurposeNone of the key randomised trials on the omission of axillary lymph node dissection (ALND) in sentinel lymph-positive breast cancer have reported external validity, even though results indicate selection bias. Our aim was to assess the external validity of the ongoing randomised SENOMAC trial by comparing characteristics of Swedish SENOMAC trial participants with non-included eligible patients registered in the Swedish National Breast Cancer Register (NKBC).MethodsIn the ongoing non-inferiority European SENOMAC trial, clinically node-negative cT1 –T3 breast cancer patients with up to two sentinel lymph...
Source: Breast Cancer Research and Treatment - January 27, 2020 Category: Cancer & Oncology Source Type: research

Significance of glucocorticoid signaling in triple-negative breast cancer patients: a newly revealed interaction with androgen signaling
ConclusionThis is the first study to reveal that the interaction of GR and AR did influence the clinical outcome of TNBC patients and GCs induced cell migration in TNBC cells. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - January 27, 2020 Category: Cancer & Oncology Source Type: research

The novel TP53 3 ′-end methylation pattern associated with its expression would be a potential biomarker for breast cancer detection
ConclusionsThe 3 ′-end methylation ofTP53 might be a crucial regulator for its expression in breast cancer, suggesting thatTP53 3 ′-end hyper-methylation associated with its lower expression could be a potential biomarker for breast cancer diagnosis. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - January 25, 2020 Category: Cancer & Oncology Source Type: research

Healthcare system distrust and the breast cancer continuum of care
ConclusionHealthcare system distrust is prevalent across many different racial and ethnic groups and operates across the entire breast cancer continuum of care. It is an important yet understudied barrier to cancer. We hope that the knowledge garnered by this study will enable researchers to form effective and targeted interventions to reduce healthcare system distrust mediated disparities in breast cancer outcomes. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - January 25, 2020 Category: Cancer & Oncology Source Type: research

Breast cancer tumor histopathology, stage at presentation, and treatment in the extremes of age
AbstractBackgroundGiven presumed differences in disease severity between young ( ≤ 45 years) and elderly (≥ 75 years) women with breast cancer, we sought to compare tumor histopathology, stage at presentation, patterns of care, and survival at the extremes of age.MethodsAdults with stages 0 –IV breast cancer in the National Cancer Database (2004–2015) were categorized by age (18–45 years, 46–74 years, ≥ 75 years) and compared. Kaplan–Meier curves were used to visualize unadjusted overall survival (OS). A Cox proportional-hazards mod...
Source: Breast Cancer Research and Treatment - January 24, 2020 Category: Cancer & Oncology Source Type: research

Red clover and lifestyle changes to contrast menopausal symptoms in premenopausal patients with hormone-sensitive breast cancer receiving tamoxifen
AbstractPurposeTo determine whether a red clover preparation plus dietary intervention administered to premenopausal women with breast cancer (BC), improves menopausal symptoms due to anti-oestrogen treatment, and hence promotes compliance with tamoxifen, prevents weight gain and is safe.MethodsSurgically-treated premenopausal women with oestrogen receptor (ER) positive disease taking tamoxifen were recruited to a prospective double-blind randomized trial (NCT03844685). The red clover group (N = 42) received one oral tablet/day (Promensil® Forte) containing 80  mg red clover extract for 24 month...
Source: Breast Cancer Research and Treatment - January 24, 2020 Category: Cancer & Oncology Source Type: research